These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 15327522

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP, Gratama JW, Lamers C, van Esser JW, Bolhuis RL, Cornelissen JJ.
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [Abstract] [Full Text] [Related]

  • 3. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
    Streeter PR, Zhang X, Tittle TV, Schön CN, Weinberg AD, Maziarz RT.
    Biol Blood Marrow Transplant; 2004 May; 10(5):298-309. PubMed ID: 15111929
    [Abstract] [Full Text] [Related]

  • 4. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kroger N.
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regulation of OX40 gene expression in graft-versus-host disease.
    Miura Y, Thoburn CJ, Bright EC, Arai S, Hess AD.
    Transplant Proc; 2005 Mar; 37(1):57-61. PubMed ID: 15808546
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 11. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K, Fan ZP, Liu QF, Zhang Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [Abstract] [Full Text] [Related]

  • 14. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, Sok A, Drabczak-Skrzypek D, Sedzimirska M, Lange A.
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [Abstract] [Full Text] [Related]

  • 15. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G, Kovochich M, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [Abstract] [Full Text] [Related]

  • 16. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease.
    Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A.
    Transplantation; 2007 Jul 15; 84(1):31-9. PubMed ID: 17627234
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
    Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB.
    Clin Cancer Res; 2006 Sep 15; 12(18):5520-5. PubMed ID: 17000688
    [Abstract] [Full Text] [Related]

  • 19. Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation.
    Nolte-'t Hoen EN, Wagenaar-Hilbers JP, Boot EP, Lin CH, Arkesteijn GJ, van Eden W, Taams LS, Wauben MH.
    Eur J Immunol; 2004 Nov 15; 34(11):3016-27. PubMed ID: 15376196
    [Abstract] [Full Text] [Related]

  • 20. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD.
    Biol Blood Marrow Transplant; 2006 Jan 15; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.